A comparison of overall survival with 40 and 50 mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data
详细信息 查看全文
- 作者：Masahiko Nakayama ; mnakayam@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Hisanori Kobayashi hkobaya1@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Tomihiro Takahara ttakahar@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Yukiko Nishimura ynishim1@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Koji Fukushima kfukush@its.jnj.com" class="auth_mail" title="E-mail the corresponding author ; Kazutake Yoshizawa kyoshiz1@its.jnj.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ovarian neoplasms ; Liposomal doxorubicin ; Propensity score ; Mortality ; Hand-foot syndrome ; Stomatitis
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：143
- 期：2
- 页码：246-251
- 全文大小：450 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Survival was compared in terms of initial dose of pegylated liposomal doxorubicin (PLD) with propensity score analysis.
- class="label">•
After matching with propensity score, the survival difference was not significant (50 vs. 40 mg/m2 PLD).
- class="label">•
Incidence and severity of palmar-plantar erythrodysesthesia and stomatitis were significantly lower with 40 mg/m2 of PLD.